ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging the company made materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA reportedly raised serious safety concerns including device malfunctions and dangerously high insulin dosing causing hypoglycemic events. The lawsuit claims Beta Bionics failed to implement meaningful corrective actions despite thousands of complaints. Investors who purchased stock between July 30, 2025 and February 24, 2026 may be eligible for compensation, with a November 3, 2026 deadline to serve as lead plaintiff.